Q-omics provides the consensus-scored NXN profile across patient tissues and cancer cell-line models. NXN expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NXN is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, NXN protein abundance shows 21,217 significant protein co-abundance associations, with the highest sampling consensus in COAD. Together, these results highlight ACC, HNSC, and COAD as cancer lineages where NXN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NXN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NXN survival associations across molecular data types. NXN RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NXN RNA expression–survival associations across cancer types. High NXN expression shows unfavorable associations in ACC, MESO, BRCA and BLCA, but favorable associations in DLBC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NXN RNA expression.
This table summarizes NXN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NXN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NXN shows lower tumor expression in KICH, LUAD and BLCA and higher tumor expression in HNSC, THCA and KIRP. The HNSC box plot shows higher NXN RNA expression in tumor versus normal tissue (log2 FC = +1.296, t-test p < 0.001).
This table shows molecular features associated with NXN in patient tissues and cancer cell lines. In patient samples, NXN shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NXN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
